IAM - Iambic Therapeutics, Inc.
SNF Emerging Watchlist(TM) tracks newly public companies positioned around emerging economic themes. Inclusion reflects SNF research interest and ongoing monitoring; it is not a recommendation to buy, sell, or hold a security.
Iambic pairs proprietary AI models with automated chemistry and biology experimentation to discover and advance medicines. One wholly owned program is in Phase 1/1b, a second reached IND submission, and collaborations provide external validation. The profile merits Candidate status, while durable clinical efficacy remains unproven.
Added to SNF Emerging Watchlist as a Candidate after the October 2026 review established a complete evidence package across platform quality, pipeline advancement, partnerships and financial runway.
Iambic offers public-market exposure to AI-enabled drug discovery with both proprietary technology and owned clinical assets. The opportunity is significant if faster discovery translates into better clinical outcomes.
Market Confirmation begins at 50/100 because IAM has only a short public trading history. Initial price performance contributes zero Emerging Score points.
Meaningful IAM1363 efficacy, clean IAM217 execution and disciplined capital use would strengthen the thesis. Clinical setbacks, uncontrolled burn or partner retrenchment would weaken it.